Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study

British Journal of Clinical Pharmacology

Volumn 75, Issue 5, 2013, Pages 1289-1298

  Van Hartingsveldt, Bart ^a   Nnane, Ivo P ^a   Bouman Thio, Esther ^a   Loza, Matthew J ^a   Piantone, Alexa ^a   Davis, Hugh M ^a   Petty, Kevin J ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

First in human study; Interleukin 13; Monoclonal antibody; Safety

Indexed keywords

CNTO 5825; IMMUNOGLOBULIN E; INTERLEUKIN 13 ANTIBODY; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ADULT; ANTICIPATORY NAUSEA AND VOMITING; ARTICLE; BACKACHE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; HYPERSENSITIVITY; IMMUNOGENICITY; INJECTION SITE REACTION; LIMB INJURY; MALE; MYALGIA; NORMAL HUMAN; OROPHARYNX PAIN; PHARMACODYNAMICS; PRIORITY JOURNAL; RHINOPHARYNGITIS; VOMITING;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-13; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84875706166     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04477.x     Document Type: Article

References (20)

1. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003; 21: 425-456.
2. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, Keegan AD, Garcia KC. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008; 132: 259-272.
3. Palmer-Crocker RL, Hughes CC, Pober JS. IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain. J Clin Invest 1996; 98: 604-609.
4. Cihakova D, Barin JG, Afanasyeva M, Kimura M, Fairweather D, Berg M, Talor MV, Baldeviano GC, Frisancho S, Gabrielson K, Bedja D, Rose NR. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol 2008; 172: 1195-1208.
5. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004; 202: 175-190.
6. Elias J. The relationship between asthma and COPD: lessons from transgenic mice. Chest 2004; 126: 111S-116.
7. Riccieri V, Rinaldi T, Spadaro A, Scrivo R, Ceccarelli F, Franco MD, Taccari E, Valesini G. Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol 2003; 22: 102-106.
8. Park SW, Ahn MH, Jang HK, Jang AS, Kim DJ, Koh ES, Park JS, Uh ST, Kim YH, Paik SH, Shin HK, Youm W, Park CS. Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function. J Korean Med Sci 2009; 24: 614-620.
9. Wills-Karp M, Finkelman FD. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal 2008; 1: pe55.
10. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
11. Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem 1997; 272: 15036-15042.
12. Nomura T, Terada N, Kim WJ, Nakano K, Fukuda Y, Wakita A, Numata T, Konno A. Interleukin-13 induces thymus and activation-regulated chemokine (CCL17) in human peripheral blood mononuclear cells. Cytokine 2002; 20: 49-55.
13. Syed F, Huang CC, Li K, Liu V, Shang T, Amegadzie BY, Griswold DE, Song XY, Li L. Identification of interleukin-13 related biomarkers using peripheral blood mononuclear cells. Biomarkers 2007; 12: 414-423.
14. Takeuchi H, Yamamoto Y, Kitano H, Enomoto T. Changes in thymus- and activation-regulated chemokine (TARC) associated with allergen immunotherapy in patients with perennial allergic rhinitis. J Investig Allergol Clin Immunol 2005; 15: 172-176.
15. Leung TF, Wong CK, Chan IH, Ip WK, Lam CW, Wong GW. Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma. J Allergy Clin Immunol 2002; 110: 404-409.
16. Sekiya T, Yamada H, Yamaguchi M, Yamamoto K, Ishii A, Yoshie O, Sano Y, Morita A, Matsushima K, Hirai K. Increased levels of a TH2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics. Allergy 2002; 57: 173-177.
17. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010; 19: 46-54.
18. Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med 2010; 10: 3.
19. Oh CK, Faggioni R, Jin F, Roskos LK, Wang B, Birrell C, Wilson R, Molfino NA. An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males. Br J Clin Pharmacol 2010; 69: 645-655.
20. Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich TX, Watson RM, Zhou S, Raible D, O'Byrne PM. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011; 183: 1007-1014.